Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
|Articles|February 24, 2021
Pain Caused by COVID-19: 7 Questions on What We Know
Author(s)Leo Robert
Pain associated with COVID-19 has many causes and may persist after the infection has resolved. Find out what you've learned about pain in the pandemic with these 7 questions.
Advertisement
Pain associated with COVID-19 infection—during the acute illness or afterward—is common and merits close attention from health care providers.
In a
Find out what you know about the pain in the pandemic with this 7-question quiz based on the review.
For more COVID-19 coverage for primary care, visit our COVID-19 Resource Page .
Advertisement
Related to this article
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
Advertisement
Advertisement